NLS Pharmaceutics Ltd

Research NLS Pharmaceutics Ltd (NCEL) on Bullrun: market cap USD 18.60M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 18.60M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025n/a-USD 8.30M-USD 2.77Mn/a2.16USD 2.20MUSD 355.00KUSD 7.25M
FY2024n/a-USD 7.20M-USD 1.07Mn/a2.43USD 650.00KUSD 7.73M-USD 8.00M
FY2023n/a-USD 3.33M-USD 3.45Mn/a1.13USD 1.15Mn/a-USD 1.20M
FY2022n/a-USD 16.50Mn/an/a-33.52USD 8.95Mn/aUSD 111.00K
FY2021n/a-USD 11.95M-USD 14.98Mn/a-1USD 5.43MUSD 0USD 542.39K

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 18.60Mn/an/an/a
20252025-12-31USD 8.66Mn/an/an/a
20242024-12-31USD 62.47Mn/an/an/a
20232023-12-29USD 19.14Mn/an/an/a
20222022-12-30USD 1.30Bn/an/an/a
20212021-12-31USD 1.05Bn/an/an/a

About NLS Pharmaceutics Ltd

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is NLS Pharmaceutics Ltd's market cap?

NLS Pharmaceutics Ltd's market capitalization is USD 18.60M.

What does NLS Pharmaceutics Ltd do?

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes.